Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27;14(2):52-61.
doi: 10.4331/wjbc.v14.i2.52.

Correlation of serum SARS-CoV-2 IgM and IgG serology and clinical outcomes in COVID-19 patients: Experience from a tertiary care centre

Mohan Suresh  1 , Pratap Kumar  1 , Prasan Kumar Panda  2 , Vikram Jain  1 , Rohit Raina  1 , Sarama Saha  3 , Subbiah Vivekanandhan  3 , Balram Ji Omar  4
Affiliations

Correlation of serum SARS-CoV-2 IgM and IgG serology and clinical outcomes in COVID-19 patients: Experience from a tertiary care centre

Mohan Suresh et al. World J Biol Chem. .

Abstract

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has become a pandemic for the last 2 years. Inflammatory response to the virus leads to organ dysfunction and death. Predicting the severity of inflammatory response helps in managing critical patients using serology tests IgG and IgM.

Aim: To investigate the correlation of the serology (IgM and IgG) with reverse transcriptase polymerase chain reaction (RT-PCR) status, disease severity [mild to critical], intensive care unit (ICU) admission, septic shock, acute kidney injury, and in-hospital mortality.

Methods: We conducted a longitudinal study to correlate serum SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) serology with clinical outcomes in coronavirus disease 2019 (COVID-19) patients. We analyzed patient data from March to December 2020 for those who were admitted at All India Institute of Medical Sciences Rishikesh. Clinical and laboratory data of these patients were collected from the e-hospital portal and analyzed. A correlation was seen with clinical outcomes and was assessed using MS Excel 2010 and SPSS software.

Results: Out of 494 patients, the mean age of patients was 48.95 ± 16.40 years and there were more male patients in the study (66.0%). The patients were classified as mild-moderate 328 (67.1%), severe 131 (26.8%), and critical 30 (6.1%). The mean duration from symptom onset to serology testing was 19.87 ± 30.53 d. In-hospital mortality was observed in 25.1% of patients. The seropositivity rate (i.e., either IgG or IgM > 10 AU) was 50%. IgM levels (AU/mL) (W = 33428.000, P ≤ 0.001) and IgG levels (AU/mL) (W = 39256.500, P ≤ 0.001), with the median IgM/ IgG levels (AU/mL), were highest in the RT-PCR-Positive group compared to RT-PCR-Negative clinical COVID-19. There was no significant difference between the two groups in terms of all other clinical outcomes (disease severity, septic shock, ICU admission, mechanical ventilation, and mortality).

Conclusion: The study showed that serology levels are high in RT-PCR positive group compared to clinical COVID-19. However, serology cannot be useful for the prediction of disease outcomes. The study also highlights the importance of doing serology at a particular time as antibody titers vary with the duration of the disease. In week intervals there was a significant correlation between clinical outcomes and serology on week 3.

Keywords: Inflammatory response; Reverse transcription polymerase chain reaction; SARS-CoV-2; Serology IgM and IgG.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: We declare that we have no conflicts of interest and it’s not funded.

Figures

Figure 1
Figure 1
Study flow chart. AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; IgG: Immunoglobulin G; IgM: Immunoglobulin M; RT-PCR: Reverse transcriptase polymerase chain reaction.
Figure 2
Figure 2
Baseline demographic characteristic of patients.
Figure 3
Figure 3
Seropositivity status with the duration of illness.
Figure 4
Figure 4
Association of coronavirus disease 2019 serology and reverse transcriptase polymerase chain reaction status.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. COVID-19 Treatment Guidelines Panel. National Institutes of Health; 2022. Coronavirus Disease 2019 [COVID-19] Treatment Guidelines; August 8, 2022 [cited August 16, 2022]. Available from: https://www.COVID-1919treatmentguidelines.nih.gov/ - PubMed
    1. COVID-19 [Internet]. CDC; 2020. Assessing Risk Factors; November 30, 2020 [Cited August 16, 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/COVID-19-data/investigations-d... as-sessing-risk-factors.html.
    1. Udwadia ZF, Tripathi AR, Nanda VJ, Joshi SR. Prognostic Factors for Adverse Outcomes in COVID-19 Infection. J Assoc Physicians India. 2020;68:62–66. - PubMed
    1. Sule WF, Oluwayelu DO. Real-time RT-PCR for COVID-19 diagnosis: challenges and prospects. Pan Afr Med J. 2020;35:121. - PMC - PubMed
    1. Lekpa FK, Njonnou SRS, Balti E, Luma HN, Choukem SP University of Dschang Taskforce for the Elimination of COVID-19 (UNITED#COVID-19) Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong. Lancet Infect Dis. 2021;21:1209. - PMC - PubMed